Items where Author is "Tarhini, AA"

Article

Retseck, J and VanderWeele, R and Lin, HM and Lin, Y and Butterfield, LH and Tarhini, AA (2016) Phenotypic and functional testing of circulating regulatory T cells in advanced melanoma patients treated with neoadjuvant ipilimumab. Journal for ImmunoTherapy of Cancer, 4 (1).

Mehta, K and Appleman, L and Wang, H and Tarhini, AA and Parikh, RA (2016) Annual hospital volume of high dose interleukin-2 and inpatient mortality in melanoma and renal cell carcinoma patients. PLoS ONE, 11 (1).

Tarhini, AA and Zahoor, H and Yearley, JH and Gibson, C and Rahman, Z and Dubner, R and Rao, UNM and Sander, C and Kirkwood, JM (2015) Tumor associated PD-L1 expression pattern in microscopically tumor positive sentinel lymph nodes in patients with melanoma. Journal of Translational Medicine, 13 (1).

Tarhini, AA and Zahoor, H and Lin, Y and Malhotra, U and Sander, C and Butterfield, LH and Kirkwood, JM (2015) Baseline circulating IL-17 predicts toxicity while TGF-β1 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma. Journal for ImmunoTherapy of Cancer, 3 (1).

Tarhini, AA and Lin, Y and Zahoor, H and Shuai, Y and Butterfield, LH and Ringquist, S and Gogas, H and Sander, C and Lee, S and Agarwala, SS and Kirwood, JM (2015) Pro-inflammatory cytokines predict relapse-free survival after one month of interferon-α but not observation in intermediate risk melanoma patients. PLoS ONE, 10 (7).

Dutcher, JP and Schwartzentruber, DJ and Kaufman, HL and Agarwala, SS and Tarhini, AA and Lowder, JN and Atkins, MB (2014) High dose interleukin-2 (Aldesleukin) - expert consensus on best management practices-2014. Journal for ImmunoTherapy of Cancer, 2 (1).

Tarhini, AA and Edington, H and Butterfield, LH and Lin, Y and Shuai, Y and Tawbi, H and Sander, C and Yin, Y and Holtzman, M and Johnson, J and Rao, UNM and Kirkwood, JM (2014) Immune monitoring of the circulation and the tumor microenvironment in patients with regionally advanced melanoma receiving neoadjuvant ipilimumab. PLoS ONE, 9 (2).

Tarhini, AA and Lin, Y and Yeku, O and LaFramboise, WA and Ashraf, M and Sander, C and Kirkwood, JM and Lee, S (2014) A four-marker signature of TNF-RII, TGF-α, TIMP-1 and CRP is prognostic of worse survival in high-risk surgically resected melanoma. Journal of Translational Medicine, 12 (1).

Ascierto, PA and Grimaldi, AM and Acquavella, N and Borgognoni, L and Calabrò, L and Cascinelli, N and Cesano, A and Del Vecchio, M and Eggermont, AM and Faries, M and Ferrone, S and Fox, BA and Gajewski, TF and Galon, J and Gnjatic, S and Gogas, H and Kashani-Sabet, M and Kaufman, HL and Larkin, J and Lo, RS and Mantovani, A and Margolin, K and Melief, C and McArthur, G and Palmieri, G and Puzanov, I and Ribas, A and Seliger, B and Sosman, J and Suenaert, P and Tarhini, AA and Trinchieri, G and Vidal-Vanaclocha, F and Wang, E and Ciliberto, G and Mozzillo, N and Marincola, FM and Thurin, M (2013) Future perspectives in melanoma research. Meeting report from the " Melanoma Bridge. Napoli, December 2nd-4th 2012". Journal of Translational Medicine, 11 (1).